Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/4/853 |
| _version_ | 1797396062699257856 |
|---|---|
| author | Giuseppe Privitera Daniela Pugliese Gian Ludovico Rapaccini Antonio Gasbarrini Alessandro Armuzzi Luisa Guidi |
| author_facet | Giuseppe Privitera Daniela Pugliese Gian Ludovico Rapaccini Antonio Gasbarrini Alessandro Armuzzi Luisa Guidi |
| author_sort | Giuseppe Privitera |
| collection | DOAJ |
| description | Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD. |
| first_indexed | 2024-03-09T00:44:52Z |
| format | Article |
| id | doaj.art-9f0474b2e06d463ab0894f5df5356726 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T00:44:52Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-9f0474b2e06d463ab0894f5df53567262023-12-11T17:36:29ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-0110485310.3390/jcm10040853Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel DiseasesGiuseppe Privitera0Daniela Pugliese1Gian Ludovico Rapaccini2Antonio Gasbarrini3Alessandro Armuzzi4Luisa Guidi5Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyCEMAD—IBD UNIT—Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, ItalyDipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyDipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyDipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyDipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, ItalyInflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.https://www.mdpi.com/2077-0383/10/4/853inflammatory bowel diseasebiological therapypredictorsbiomarkers |
| spellingShingle | Giuseppe Privitera Daniela Pugliese Gian Ludovico Rapaccini Antonio Gasbarrini Alessandro Armuzzi Luisa Guidi Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases Journal of Clinical Medicine inflammatory bowel disease biological therapy predictors biomarkers |
| title | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases |
| title_full | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases |
| title_fullStr | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases |
| title_full_unstemmed | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases |
| title_short | Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases |
| title_sort | predictors and early markers of response to biological therapies in inflammatory bowel diseases |
| topic | inflammatory bowel disease biological therapy predictors biomarkers |
| url | https://www.mdpi.com/2077-0383/10/4/853 |
| work_keys_str_mv | AT giuseppeprivitera predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases AT danielapugliese predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases AT gianludovicorapaccini predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases AT antoniogasbarrini predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases AT alessandroarmuzzi predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases AT luisaguidi predictorsandearlymarkersofresponsetobiologicaltherapiesininflammatoryboweldiseases |